Brief: Roivant Sciences Q2 Operating Expenses USD 307.804 Million
10/11/2025 12:00
Nov 10 (Reuters) - Roivant Sciences Q2 EPS USD -0.17. Q2 revenue USD 1.571 million Q2 net income USD -166.039 million Q2 income from operations USD -306.233 million vs. IBES estimate USD -277.8 million
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple